Author: John

Since mid-2024, ChatGPT has emerged as one of the most visited websites globally, surpassing major platforms like Amazon, X, Reddit, WhatsApp, and Wikipedia in monthly visitors. According to web analytics firm Similarweb, ChatGPT now ranks as the fifth most popular site worldwide, trailing only Google, YouTube, Facebook, and Instagram. This milestone reflects not only the rapid adoption of AI chatbots but also the growing influence of generative AI in everyday digital interactions. Monthly visits to ChatGPT reached an impressive 6.3 billion in September 2025, capturing the vast majority of traffic across AI platforms. As usage expands across age groups and…

Read More

IBM is reportedly in advanced talks to acquire Confluent, a leading data infrastructure company, for approximately $11 billion, signaling a significant step in its cloud expansion strategy. Confluent’s open-source platform enables businesses to process vast streams of real-time data, ranging from financial transactions to website activity, making it a key asset in today’s data-driven economy. The acquisition, which could be announced imminently, reflects IBM’s efforts to strengthen its cloud software offerings amid rising demand for artificial intelligence and data infrastructure solutions. Under CEO Arvind Krishna, IBM has increasingly prioritized software and cloud services, following prior acquisitions like HashiCorp. This move…

Read More

Indian pharmaceutical tycoon Kiran Mazumdar-Shaw has taken a decisive step to strengthen Biocon’s global ambitions by fully consolidating Biocon Biologics in a landmark $5.5 billion buyout. The transaction brings Biocon’s biosimilars and generics businesses under a unified corporate structure, reinforcing its position as a major force in the international biopharmaceutical industry. By acquiring the remaining shares from financial and strategic investors, Biocon aims to simplify operations, improve capital efficiency, and sharpen its focus on high-growth therapeutic areas such as diabetes, oncology, and immunology. The move reflects Mazumdar-Shaw’s long-term strategy to build a globally competitive healthcare company capable of delivering affordable,…

Read More